{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:56:20Z","timestamp":1789188980098,"version":"build-2803163510"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2013,7,19]],"date-time":"2013-07-19T00:00:00Z","timestamp":1374192000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0069288","type":"journal-article","created":{"date-parts":[[2013,7,19]],"date-time":"2013-07-19T20:55:05Z","timestamp":1374267305000},"page":"e69288","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":109,"title":["Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa"],"prefix":"10.1371","volume":"8","author":[{"given":"Joseph N.","family":"Jarvis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Lawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Meintjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Cleary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,7,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ijid.2005.07.004","article-title":"Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus","volume":"10","author":"C Bekondi","year":"2006","journal-title":"Int J Infect Dis"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa065711","article-title":"Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa","volume":"357","author":"M Scarborough","year":"2007","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-2334-10-67","article-title":"Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases","volume":"10","author":"JN Jarvis","year":"2010","journal-title":"BMC Infect Dis"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1086\/518607","article-title":"Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole","volume":"45","author":"T Bicanic","year":"2007","journal-title":"Clin Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1086\/588792","article-title":"High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial","volume":"47","author":"T Bicanic","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jinf.2010.03.007","article-title":"Outcomes of cryptococcal meningitis in antiretroviral naive and experienced patients in South Africa","volume":"60","author":"JN Jarvis","year":"2010","journal-title":"J Infect"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1086\/587667","article-title":"Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy","volume":"46","author":"A Kambugu","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"e8630","DOI":"10.1371\/journal.pone.0008630","article-title":"Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa","volume":"5","author":"JV Lightowler","year":"2010","journal-title":"PLoS ONE 2010"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.7196\/SAMJ.4378","article-title":"Poor long-term outcomes from cryptococcal meningitis in rural South Africa","volume":"101(4)","author":"RJ Lessells","year":"2011","journal-title":"South African Medical Journal"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","article-title":"Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS","volume":"23","author":"BJ Park","year":"2009","journal-title":"Aids"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/QAD.0b013e3283383aeb","article-title":"Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme","volume":"24","author":"JN Jarvis","year":"2010","journal-title":"Aids"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators","volume":"338","author":"FJ Palella Jr","year":"1998","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1086\/314606","article-title":"Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group","volume":"179","author":"RA Hajjeh","year":"1999","journal-title":"J Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1086\/368091","article-title":"The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992\u20132000","volume":"36","author":"SA Mirza","year":"2003","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/clinids\/23.1.82","article-title":"Epidemiology of cryptococcosis in France: a 9-year survey (1985\u20131993). French Cryptococcosis Study Group","volume":"23","author":"F Dromer","year":"1996","journal-title":"Clin Infect Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1097\/QAD.0b013e32830007cd","article-title":"Early Mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa","volume":"22","author":"S Lawn","year":"2008","journal-title":"Aids"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1056\/NEJM199503163321102","article-title":"A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group","volume":"332","author":"WG Powderly","year":"1995","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1086\/514744","article-title":"Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"28","author":"DS McKinsey","year":"1999","journal-title":"Clin Infect Dis"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1468-1293.2001.00060.x","article-title":"A randomized, double-blind, placebo-controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection","volume":"2","author":"DE Smith","year":"2001","journal-title":"HIV Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1468-1293.2004.00201.x","article-title":"A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency","volume":"5","author":"P Chetchotisakd","year":"2004","journal-title":"HIV Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1086\/338154","article-title":"A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand","volume":"34","author":"S Chariyalertsak","year":"2002","journal-title":"Clin Infect Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1473-3099(11)70245-6","article-title":"Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial","volume":"11(12)","author":"R Parkes-Ratanshi","year":"2011","journal-title":"The Lancet infectious diseases"},{"key":"ref23","first-page":"CD004773","article-title":"Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV","volume":"2005","author":"LW Chang","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/clinids\/23.4.827","article-title":"Serum cryptococcal antigen in patients with AIDS","volume":"23","author":"M Feldmesser","year":"1996","journal-title":"Clin Infect Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1468-1293.2004.00199.x","article-title":"Primary prophylaxis for cryptococcal meningitis","volume":"5","author":"L John","year":"2004","journal-title":"HIV Med"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1177\/0272989X9701700402","article-title":"The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infections in AIDS patients","volume":"17","author":"JA Scharfstein","year":"1997","journal-title":"Med Decis Making"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1086\/344902","article-title":"Prevention of human immunodeficiency virus-related opportunistic infections in France: a cost-effectiveness analysis","volume":"36","author":"Y Yazdanpanah","year":"2003","journal-title":"Clin Infect Dis"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.279.2.130","article-title":"The cost-effectiveness of preventing AIDS-related opportunistic infections","volume":"279","year":"1998","journal-title":"Jama"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1086\/517056","article-title":"The hidden danger of primary fluconazole prophylaxis for patients with AIDS","volume":"26","author":"J Berg","year":"1998","journal-title":"Clin Infect Dis"},{"key":"ref30","first-page":"795","article-title":"Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with\/without fluconazole prophylaxis","volume":"89","author":"W Manosuthi","year":"2006","journal-title":"J Med Assoc Thai"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1128\/AAC.44.6.1585-1587.2000","article-title":"Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses study group","volume":"44","author":"M Goldman","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/QAI.0b013e31815bad0c","article-title":"The impact of primary prophylaxis for cryptococcosis on fluconazole resistance in Candida species","volume":"47","author":"A Apisarnthanarak","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1086\/597262","article-title":"Screening for Cryptococcal Antigenemia in Patients Accessing an Antiretroviral Treatment Program in South Africa","volume":"48","author":"JN Jarvis","year":"2009","journal-title":"Clin Infect Dis"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"FA Sonnenberg","year":"1993","journal-title":"Medical Decision Making"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","article-title":"An Introduction to Markov Modelling for Economic Evaluation","volume":"13","author":"A Briggs","year":"1998","journal-title":"Pharmacoeconomics"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00002030-198902000-00004","article-title":"The value of cryptococcal serum antigen screening among HIV-positive\/AIDS patients in Kinshasa, Zaire","volume":"3","author":"P Desmet","year":"1988","journal-title":"Aids"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00126334-200307010-00019","article-title":"Systematic screening of cryptococcal antigenemia in HIV-positive adults in Uganda","volume":"33","author":"JM Tassie","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1365-3156.2007.01874.x","article-title":"Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda","volume":"12","author":"CA Liechty","year":"2007","journal-title":"Trop Med Int Health"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/655143","article-title":"Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count<or = 100 cells\/microL who start HIV therapy in resource-limited settings","volume":"51","author":"DB Meya","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref40","first-page":"495","article-title":"The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya. Trop Med Int Health","volume":"18(4)","author":"AC Meyer","year":"2013"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/QAI.0b013e31811ed32c","article-title":"Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients","volume":"45","author":"R Micol","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jinf.2010.03.015","article-title":"The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts","volume":"60","author":"P Pongsai","year":"2010","journal-title":"J Infect"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/00002030-200205030-00009","article-title":"Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults","volume":"16","author":"N French","year":"2002","journal-title":"Aids"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/01.qai.0000225729.79610.b7","article-title":"CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment","volume":"42","author":"CB Holmes","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1086\/657405","article-title":"Cryptococcal antigen screening for patients initiating antiretroviral therapy: time for action","volume":"51","author":"JN Jarvis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/QAD.0b013e3283536a93","article-title":"Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial","volume":"26(9)","author":"JN Jarvis","year":"2012","journal-title":"AIDS"},{"key":"ref47","first-page":"579","article-title":"Cryptococcal antigenemia in HIV-infected patients [abstract no. 93]","volume":"19","author":"C Yuen","year":"1994","journal-title":"Clin Infect Dis"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1478-7547-4-20","article-title":"The cost-effectiveness of Antiretroviral Treatment in Khayelitsha, South Africa: a primary data analysis","volume":"4","author":"S Cleary","year":"2006","journal-title":"Cost effectiveness and resource allocation"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hec.4730030206","article-title":"Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis","volume":"3","author":"A Briggs","year":"1994","journal-title":"Health Economics"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"e13856","DOI":"10.1371\/journal.pone.0013856","article-title":"Cost-Effectiveness of Primary Prophylaxis of AIDS Associated Cryptococcosis in Cambodia","volume":"5","author":"R Micol","year":"2010","journal-title":"PLoS ONE"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/cid\/cir613","article-title":"Evaluation of a novel point of care cryptococcal antigen (CRAG) test on serum, plasma and urine from patients with HIV-associated cryptococcal meningitis","volume":"53(10)","author":"JN Jarvis","year":"2011","journal-title":"Clin Infect Dis"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1472-6963-7-80","article-title":"Healthcare utilization of patients accessing an African national treatment program","volume":"7","author":"G Harling","year":"2007","journal-title":"BMC Health Serv Res"},{"key":"ref53","first-page":"320","article-title":"Clinical and financial burdens of secondary level care in a public sector antiretroviral roll-out setting (G. F. Jooste Hospital)","volume":"99","author":"S Kevany","year":"2009","journal-title":"S Afr Med J"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0069288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T20:26:20Z","timestamp":1646166380000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0069288"}},"subtitle":[],"editor":[{"given":"T. Mark","family":"Doherty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,7,19]]},"references-count":53,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2013,7,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0069288","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,19]]}}}